Global Inhalation and Nasal Spray Generic Drugs Industry Gears Up for Consistent Growth: Anticipates an Impressive 8.96% CAGR During the Forecast Period. With a Current Valuation of US$ 20.78 Billion in 2023, the Market is Poised to Surge to US$ 49.01 Billion by 2033.
The Market’s Upward Trajectory Fueled by the Expanding Older Population, Prone to Chronic Respiratory Ailments. According to the World Health Organisation, by 2030, one in every six individuals worldwide will be 60 or older, with the global figure estimated to reach 2.1 billion by 2050. Additionally, the Asthma and Allergy Foundation of America predicts that 7.8% of the United States population over the age of 65 will have asthma by 2020.
Request a Sample Report Now to get Premium Insights
https://www.futuremarketinsights.com/reports/sample/rep-gb-15759
However, strict rules in other countries, such as Mexico and Russia, may limit demand for generic inhalation and nasal spray therapies. For example, COFEPRIS, Mexico’s regulatory authority, has adopted new criteria for generic medicine registration that may remove patents for new therapeutic uses. Furthermore, COFEPRIS has a unique generic medicine approval process in Mexico.
Key Takeaways
- Throughout the projection period, the Asia-Pacific area is expected to grow at a profitable CAGR of 11.23%. The region’s expansion has been largely attributed to the building of strategic alliances in the region to assist the development of generic products.
- North America maintained its market leadership in 2021, with a revenue share larger than 35.0%. Aside from the increasing frequency of chronic respiratory difficulties, the introduction of new products, the completion of acquisitions, and the establishment of partnerships are all important elements in the region’s growth.
- Retail pharmacies had the highest revenue share in 2021, accounting for more than 55.0% of total revenue, owing to rising healthcare expenses and increased demand for generic medications.
- Because of attractive reimbursement regulations and an aging population, homecare will account for more than 50.0% of total money earned in 2021.
- In 2021, the adult patient segment accounted for more than 40.0% of total revenue. The key driver of the segment’s growth is a rise in the number of adult asthma and COPD patients.
- Because bronchodilators are widely used to treat respiratory disorders such as asthma and COPD all over the world, the bronchodilators market segment accounted for more than 25.0% of total revenue in 2021.
Discovering the assumptions behind the study. Ask Our Analyst More About Report
https://www.futuremarketinsights.com/ask-question/rep-gb-15759
Competitive Landscape
Growth initiatives, such as product innovation, regulatory approval of new products, and mergers and acquisitions, are a primary emphasis of the Global inhalation and nasal spray generic drugs industry leaders. For instance, Cipla Inc. submitted an ANDA for a generic version of Advair Diskus, fluticasone propionate, and salmeterol inhalation powder in May 2020. Phase three trials of the product were successfully completed by the company in April 2020. The following companies are leaders in the global market for generic inhalers and nasal sprays:
- Mylan N.V.
- Akorn, Operating Company LLC
- Cipla Inc.
- Sandoz International GmBH (Novartis AG)
- Apotex Inc.
- Hikma Pharmaceuticals PLC
- Sun Pharmaceuticals Industries Ltd.
- Beximco Pharmaceuticals Ltd
More insights available
North America is the largest inhalation and nasal spray generic market, driven by the high prevalence of respiratory diseases, a large aging population, and a well-established healthcare system. The United States is the dominant player in the region, with a significant share of the market.
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/15759
Key Segments in the Global Inhalation and Nasal Spray Generic Drugs Industry
Drug Class:
- Bronchodilators
- Combination Drugs
- Corticosteroids
- Decongestant Sprays
- Antihistamines
- Others
Indication:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Allergic Rhinitis
- Others
Patient Demographics:
- Geriatric Patient
- Adult Patient
- Paediatric Patient
End-user:
- Hospitals
- Homecare
- Others
Distribution Channel:
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacies
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
